News Column

Reports Summarize Monoclonal Antibodies Findings from R. von Moos and Co-Authors (Reducing the burden of bone metastases: current concepts and...

July 16, 2014



Reports Summarize Monoclonal Antibodies Findings from R. von Moos and Co-Authors (Reducing the burden of bone metastases: current concepts and treatment options)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology. According to news originating from Chur, Switzerland, by NewsRx correspondents, research stated, "Bone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment."

Our news journalists obtained a quote from the research, "PubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts. Bone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonate zoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise."

According to the news editors, the research concluded: "Recent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases."

For more information on this research see: Reducing the burden of bone metastases: current concepts and treatment options. Supportive Care In Cancer, 2013;21(6):1773-83. Supportive Care In Cancer can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Supportive Care In Cancer - www.springerlink.com/content/0941-4355/)

The news correspondents report that additional information may be obtained from R. von Moos, Medical Oncology, Haematology, Kantonsspital Graubunden, 7000, Chur, Switzerland. Additional authors for this research include C. Sternberg, J.J. Body and C. Bokemeyer (see also Biotechnology).

The publisher's contact information for the journal Supportive Care In Cancer is: Springer, 233 Spring Street, New York, NY 10013, USA.

Keywords for this news article include: Chur, Biotechnology, Pharmaceuticals, Drugs, Europe, Hormones, Denosumab, Switzerland, Bone Research, Immunotherapy, Bisphosphonates, Zoledronic Acid, Monoclonal Antibodies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters